Lynn Henry N, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics Investigators. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat. 2009 Oct;117(3):571-5.  

Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oeterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V and COBRA Investigators. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 2009 Aug;9(4):258-64.  

Jeong S, Woo MM, Flockhart DA, Desta Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009 Oct;64(5):867-75.  

Zhang X, Galinsky RE, Kimura RE, Quinney SK, Jones DR, Hall SD. Inhibition of CYP3A by erythromycin: In Vitro - in vivo correlation in rats. Drug Metab Dispos. 2009 Oct 1.  

Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA, Nguyen A, Li L, Mi D, Skaar TC, Jin Y. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat. 2008 Dec 12.  

Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S, Nguyen A, Schott A, Hayden J, Lemler S, Storniolo AM, Flockhart DA, Stearns V. Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen Therapy. J Clin Oncol. 2008 Nov 17.  

Li L, Yu M, Jason RD, Shen C, Azzouz F, McLeod HL, Borges-Gonzales S, Nguyen A, Skaar T, Desta Z, Sweeney CJ, Flockhart DA. A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. J Biopharm Stat. 2008;18(6):1150-77.  

Haas DM, Renbarger JL, Meslin EM, Drabiak K, Flockhart D. Patient attitudes toward genotyping in an urban women's health clinic. Obstet Gynecol. 2008 Nov;112(5):1023-8.  

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 2008 Oct;9(10):1445-58.  

Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry. 2008 Oct;165(10):1251-5.  

Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD; ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 1;26(28):4672-8.  

Quinney SK, Galinsky RE, Jiyamapa-Serna VA, Chen Y, Hamman MA, Hall SD, Kimura RE. Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Dispos. 2008 Jun;36(6):1097-101.  

Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008 Feb;10(2):139-50. 

Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, Hamman MA, Phillips S, Hilligoss J, Hall SD. Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects. Clin Pharmacol Ther. 2007 Nov;82(5):579-85.  

Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T, Flockhart DA. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat. 2007 Sep 20.  

Jones DR, Ekins S, Li L, Hall SD. Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos. 2007 Sep;35(9):1466-75.  

Robarge JD, Li L, Desta Z, Nguyen A, Flockhart DA. The star-allele nomenclature: retooling for translational genomics. Clin Pharmacol Ther. 2007 Sep;82(3):244-8.  

Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, Jin Y, Blanche P, Li L, Lemler S, Hayden J, Krauss RM, Desta Z, Flockhart DA, Hayes DF. Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen. Clin Pharmacol Ther. 2007 Aug 22.  

Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol. 2007 Jul 17.  

Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007 Jun;8(6):547-558.  

Derby MA, Zhang L, Chappell JC, Gonzales CR, Callaghan JT, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Mitchell MI. The Effects of Supratherapeutic Doses of Duloxetine on Blood Pressure and Pulse Rate. J Cardiovasc Pharmacol. 2007 Jun; 49(6):384-393. 

Dennison JB, Jones DR, Renbarger JL, Hall SD. Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes. J Pharmacol Exp Ther. 2007 May;321(2):553-63.  

Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, Hamman MA, Phillips S, Hilligoss J, Hall SD. Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects. Clin Pharmacol Ther. 2007 Apr 18. 

Lu Zhang, Jill Chappell, Celedon R. Gonzales, David Small, Mary P. Knadler, JT Callaghan, Jennie L. Francis, Durisala Desaiah, Mark Leibowitz, Larry Ereshefsky, David Hoelscher, Philip T. Leese, and Michael Derby. QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study. J Cardiovasc Pharmacol 2007 Mar; 49(3):146-153. 

Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD, Chalasani N. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 2007 Mar;5(3):388-93. 

Li L, Yu M, Chin R, Lucksiri A, Flockhart DA, Hall SD. Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med. 2007 Mar 14. 

Nguyen A, Desta Z, Flockhart DA. Enhancing race-based prescribing precision with pharmacogenomics. Clin Pharmacol Ther. 2007 Mar;81(3):323-5. 

Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I; Pharmacogenetics Research Network. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar;81(3):328-45. 

Shin JG, Kang WK, Shon JH, Arefayene M, Yoon YR, Kim KA, Kim DI, Kim DS, Cho KH, Woosley RL, Flockhart DA. Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol. 2007 Feb;63(2):206-15. 

Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, Baker B, Klick-Davis A, Desta Z, Burt T. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007 Feb;27(1):28-34.  

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007 Jan;101(1):113-21. 

Zhang X, Jones DR and Hall SD. Mechanism-based inhibition of cytochrome P450: In vitro kinetics and in vitro-in vivo correlations. In: Drug-drug interactions: From basic pharmacokinetic concepts to marketing issues. Rodrigues AD, Publisher: Marcel Dekker, New York, NY, 2007, Second Edition.

Hall SD and Desai M. QT analysis. Encyclopedia of Biopharmaceutical Statistics. QT Analysis. Aug 15, 2006. 

Lam YWF, Hall SD and Huang S-M. Drug interactions with botanical products. In: Herbal Supplement-Drug Interactions. Drugs and the Pharmaceutical Sciences, Vol.162. Ed: Lam YWF, Huang S-M and Hall SD. Taylor and Francis Health Sciences, 2006.

Herbal Supplement-Drug Interactions. Drugs and the Pharmaceutical Sciences, Vol.162. Editors: Lam YWF, Huang S-M and Hall SD. Publisher: Taylor and Francis Health Sciences, 2006 (ISBN: 0-8247-2538-7).

Brater DC and Hall SD: Disposition and dose requirements of drugs in renal insufficiency. IN: The Kidney: Physiology and Pathophysiology. Editors: Alpern RJ and Hebert SC. Publisher: Elsevier Inc., San Diego, CA. Fourth Edition, 2006.

Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006 Jul;80(1):61-74. 

Evans BJ, Flockhart DA. The unfinished business of U.S. drug safety regulation. Food Drug Law J. 2006;61(1):45-63. 

Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2006 Aug 25. 

Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer. 2006 Nov;6(11):886-93. 

Sandrim VC, Yugar-Toledo JC, Desta Z, Flockhart DA, Moreno H Jr, Tanus-Santos JE. Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens. 2006 Dec;24(12):2393-7.  

Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST; Pharmacogenetics Research Network. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006 Nov 21;145(10):749-57. 

BJ Evans Distinguishing Product and Practice Regulation in Personalized Medicine Clin Pharmacol Ther 81: 288-293; 

Grabinski JL, Smith LS, Chisholm GB, Drengler R, Rodriguez GI, Lang AS, Kalter SP, Garner AM, Fichtel LM, Hollsten J, Pollock BH, Kuhn JG. Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy Breast Cancer Res Treat. 2006 Jan;95(1):13-6. 

Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA, Skaar TC. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2006 May 11. 

Dennison J, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006 May 5. 

Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol. 2006 Apr 16. 

Chien JY, Lucksiri A, Ernest Ii CS, Gorski JC, Wrighton SA, Hall SD. Stochastic Prediction of CYP3A-Mediated Inhibition of Midazolam Clearance by Ketoconazole. Drug Metab Dispos. 2006 Apr 12. 

Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006 Mar;79(3):218-30. 

Schneider BP, Skaar TC, Sledge GW, Badve S, Li L, Flockhart DA. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat. 2006 Feb 28. 

Bernard S, Neville KA, Nguyen AT, Flockhart DA Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications. Oncologist. 2006 Feb;11(2):126-35. 

Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ, Lennox JL, Klotman PE, Nachman SA, Hall SD, Szczech LA. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 40(11):1559-85, 2005.

Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch F, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN Pharmacogenetics of Tamoxifen Biotransformation is Associated with Clinical Outcomes of Efficacy and Hot Flashes J Clin Oncol. 2005 Dec 20;23(36):9312-8. 

Andersson T, Flockhart DA, Goldstein DB, Huang SM, Kroetz DL, Milos PM, Ratain MJ, Thummel K. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005 Dec;78(6):559-81. 

Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, Tanus-Santos JE. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics. 2005 Aug;15(8):565-570. 

Rae JM, Goetz MP, Hayes DF, Ingle JN, Li L, Storniolo AM, Stearns V, Flockhart DA. CYP2D6 genotype and tamoxifen response. Breast Cancer Res. 2005 Jul 29;7(5):E6. 

Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, Macleod SL, Kadlubar FF, Ambrosone CB. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005 Jun;91(3):249-58. 

Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, Tashima KT, Roland M, Franceschini N, Palella FJ, Lennox JL, Klotman PE, Nachman SA, Hall SD, Szczech LA. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005 Jun 1;40(11):1559-85. 

Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005 May;55(5):471-8. 

Liangpunsakul S, Kolwankar D, Pinto A, Gorski JC, Hall SD, Chalasani N. Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology. 2005 May;41(5):1144-50. 

Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos. 2005 Apr 8; [Epub ahead of print]  

Pinto AG, Horlander J, Chalasani N, Hamman M, Asghar A, Kolwankar D, Hall SD. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol. 2005 Apr;59(4):440-6. 

Pinto AG, Wang YH, Chalasani N, Skaar T, Kolwankar D, Gorski JC, Liangpunsakul S, Hamman MA, Arefayene M, Hall SD. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther. 2005 Mar;77(3):178-88. 

Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, Li L, Hall SD, Chalasani N. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol. 2005 Mar 1;95(5):691-4. 

Wang YH, Jones DR, Hall SD. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.

Ernest CS 2nd, Hall SD, Jones DR. Mechanism-Based Inactivation of CYP3A. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91. 

Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, Cadman P, O'connor DT, Wagner U, Fineberg NS, Weinberger MH. Association Between the CYP3A5 Genotype and Blood Pressure. Hypertension. 2005 Feb;45(2):294-8. 

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005 Jan 5;97(1):30-9. 

Li L, Desai M, Desta Z, Flockhart D. QT analysis: a complex answer to a 'simple' problem. Stat Med. 2004 Sep 15;23(17):2625-43. 

Michael R. Uhing, David W. A. Beno, Vanida A. Jiyamapa-Serna, Yong Chen, Raymond E. Galinsky, Stephen D. Hall, and Robert E. Kimura The effect of anesthesia and surgery on CYP3A activity in rats. Drug Metab Dispos 2004 32: 1325-1330. 

Evans BJ, Flockhart DA and Meslin EM. Commentary: Creating incentives for genomic research to improve targeting of therapies. Nature Medicine. Dec 2004;10(12):1-3.

Vitseva O, Flockhart DA, Jin Y, Varghese S, Freedman JE. The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Ther. 2004 Oct 27 [Epub ahead of print]  

Harvey AT, Flockhart D, Gorski JC, Greenblatt DJ, Burke M, Werder S, Preskorn SH. Intramuscular haloperidol or lorazepam and QT interval in schizophrenia. J Clin Pharmacol. 2004 Oc;44(10):1173-84.  

Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6.  

Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.  

Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.  

Uhing MR, Beno DW, Jiyamapa-Serna VA, Chen Y, Galinsky RE, Hall SD, Kimura RE. The effect of anesthesia and surgery on CYP3A activity in rats. Drug Metab Dispos. 2004 Nov;32(11):1325-30.  

Le Corre P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TC, Ho H, Levere R, Smith DW, Ziegler MG, Insel PA, Schork NJ, Flockhart DA, O'Connor DT. Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther 2004 Aug;76(2):139-53.  

Takeda K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 2004 Jul;50(7):2202-10. 

Bouker KB, Skaar TC, Fernandez Dr, O'Brien KA, Riggins RB, Cao D, Clarke R. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Res. 2004 Jun 1;64(11):4030-9.  

Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Raimondi SC, Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Lim R, Lim HL, Ong AB, Lee HS, Kuehl P, Zhang J, Lin Y, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacolog Rev. 2004 Jun;56(2):159.  

Flores DL, Alvarado I, Wong ML, Licinio J, Flockhart D. Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans. Ann Intern Med. 2004 Jun 1;140(11):W71.  

MacFadyen RJ, Gorski JC, Brater DC, Struthers AD. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol. 2004 May,57(5):622-31.  

Rosenshein B, Flockhart DA, Ho H. Induction of testosterone metabolism by esomeprazole in a CYP2C19*2 heterozygote. Am J Med Sci. 2004 May;327(5):289-93.  

Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 May 24.  

Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004 May;126(5):1287-92.  

Flockhart DA, Nelson HS. Single isomer versus racemate: is there a difference? Clinical comparisons in allergy and gastroenterology. CNS Spectr. 2002 Apr;7(4 Suppl):23-7.  

Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC. Pharmacological characterization of 4-hydroxy- N -desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004 May;85(2):151-9.  

Xinzhu Pu, Linda S. Lee, Raymond E. Galinsky and Gary P. Carlson Evaluation of a Rat Model versus a Physiologically Based Extraction Test for Assessing Phenanthrene Bioavailability from Soils Toxicological Sciences 79, 10-17 (2004).  

Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J. 2004 Mar 16.  

Huang S-M, Hall SD, Watkins PB, MD, Serabjit-Singh C, Betz JM, Hoffman FA, MD, Love L, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, and Murray MD. Drug interactions with herbal products and food: A conference report. Clin Pharmacol Ther. 2004 Jan;75(1):1-12.  

Gorski JC, Huang S-M, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M and Hall SD. The effect of echinacea on cytochrome p450 activity in vivo. Clin Pharmacol Ther, 75:89-100, 2004.  

Wang Y-H, Jones DR and Hall SD. Prediction of in vivo drug interactions of cytochrome P450 3A by verapamil based on a mechanism-based inhibition model. Drug Metab Dispos. 2004 Feb;32(2):259-66.  

Gorski JC, Vanaprasat S, Bruce M, Haehner-Daniels BD and Hall SD. Induction of intestinal wall and hepatic CYP3A activity by rifampin: effects of advanced age and gender. Clin Pharmacol Ther, 74: 275-287, 2003.  

Hall SD, Wang Z, Huang S-M, Hamman MA, Vasavada N, Adigun AQ, Hilligoss J, Miller M, Gorski JC. The interaction between Saint John's wort and an oral contraceptive. Clin Pharmacol Ther, 74:525-535, 2003.  

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64. 

Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol. 2003 Dec;163(6):2271-6. 

Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD. Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics. 2003 Aug;13(8):501-507. 

Desai M, Li L, Desta Z, Malik M, Flockhart D. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol. 2003 Jun;55(6):511-7. 

Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: Application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):245-53. 

Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y, Desta Z, Flockhart DA. Pharmacokinetics and QT interval pharmacodyanamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J. 2003;3(2):105-13. 

Ward BA, Gorski CJ, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDs therapy and utility of efavirenz as substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003 Jul;306(1):287-300. 

Arefayene M, Skaar TC, Zhao X, Rae JM, Tanus-Santos JE, Brinkmann U, Brehm I, Salat U, Nguyen A, Desta Z, Flockhart DA. Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19. Pharmacogenetics 2003 Apr;13(4):199-206. 

Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 2003 Mar;37(3):544-50. 

Flockhart DA and Rae JM. Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J. 2003;3(1):3-5. 

Altman RB, Flockhart DA, Sherry ST, Oliver DE, Rubin DL, Klein TE. Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 2003 Jan;13(1):3-5. 

Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol. 2003 Jan;55(1):77-85. 

Acosta EP, Gerber JG and Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Research and Human Retroviruses 18(12): 825-834, 2002.

Shaw AA, Hall SD, Franklin MR and Galinsky RE. The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Disp, 30:177-182, 2002. 

Chalasani N, Gorski JC, Patel NH, Hall SD and Galinsky RE. Hepatic and intestinal cytochrome P450 activity in cirrhosis: Effects of transjugular intrahepatic portasystemic shunts. Letter to the Editor. Hepatology, 35:1550, 2002. 

Zhoa X-J, Jones DR and Hall SD. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and tamoxifen metabolites. Xenobiotica 32: 863-878, 2002. 

Miyata A, Zipes DP, Hall SD and Rubart M. KB-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. Circulation 106: 1410-1419, 2002. 

Williams AJ, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD and Wrighton SA.
Differential modulation of UGT1A1-catalyzed estradiol-3-glucuronidation by UGT1A1 substrates and other compounds in human liver microsomes. Drug Metab Disp 30: 1266-1273, 2002. 

Flockhart DA, Dos Santos JE. Ethnic, racial, and sex-specific factors are important in cardiovascular pharmacotherapeutics. Arch Intern Med 2002 Nov 25;162(21):2494-5. 

Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA. Inhibitory Effects of Tricyclic Antidepressants (TCAs) on Human Cytochrome P450 Enzymes in Vitro: Mechanism of Drug Interaction Between TCAs and Phenytoin. Drug Metab Dispos. 2002 Oct 1;30(10): 1102-1107. 

Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. Clin Pharmacokinet. 2002;41(12):913-58. 

Jan MW, ZumBrunnen TL, Kazmi YR, VanDenBerg CM, Desai HD, Weidler DJ, Flockhart DA. Pharmacokinetics of Fluvoxamine in Relation to CYP2C19 Phenotype and Genotype. Drug Metabol Drug Interact. 2002;19(1):1-11. 

Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, Freedman JE. Effects of Endothelial Nitric Oxide Synthase Gene Polymorphisms on Platelet Function, Nitric Oxide Release, and Interactions with Estradiol. Pharmacogenetics. 2002 Jul;12(5):407-13. 

Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. 

Flockhart DA, Usdin Yasuda S, Pezzullo JC, Knollmann BC. Teaching rational prescribing: a new clinical pharmacology curriculum for medical schools. Naunyn Schmiedebergs Arch Pharmacol. 2002 Jul;366(1):33-43. 

Gu Z, Lee RY, Skaar TC, Bouker KB, Welch JN, Lu J, Liu A, Zhu Y, Davis N, Leonessa F, Brunner N, Wang Y, Clarke R. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). Cancer Res. 2002 Jun 15;62(12):3428-37. 

Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther. 2002 Jun;71(6):414-20. 

Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos. 2002 May;30(5):525-30. 

Desta Z, Soukhova N, Flockhart DA. In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin. J Clin Psychopharmacol. 2002 Apr;22(2):162-8. 

Desta Z , Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos. 2002 Mar;30(3):336-43. 

Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, Shin JG. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics. 2002 Mar;12(2):111-9. 

Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002 Feb 25;162(4):405-12. 

Marino G, Rustgi VK, Salzberg G, Johnson LB, Kuo PC, Plotkin JS, Flockhart DA. Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Aliment Pharmacol Ther. 2002 Feb;16(2):235-42. 

Asghar A, Gorski JC , Haehner-Daniels B, Hall SD. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos. 2002 Jan;30(1):20-6. 

Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, Hall SD. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol. 2002 Jan;53(1):67-74. 

Jones DR and Hall SD. Mechanism-based inhibition of cytochrome P450: In vitro kinetics and in vitro-in vivo correlations. In: Drug-drug interactions: From basic pharmacokinetic concepts to marketing issues. Rodrigues AD, Pub:Marcel Dekker, New York, NY, 2001.

Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology. 2001 Dec;34(6):1103-8. 

Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001 Dec;299(3):849-57. 

Tanus-Santos JE, Desai M, Flockhart DA., OMIM Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics. 2001 Nov;11(8):719-25. 

Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR Jr, Schuetz EG, Boguski MS. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001 Oct;11(7):555-72. 

Desta Z, Kivisto KT, Lilja JJ, Backman JT, Soukhova N, Neuvonen PJ, Flockhart DA. Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. Br J Clin Pharmacol. 2001 Oct;52(4):399-407. 

Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001 Oct;70(4):317-26. 

Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Olanzapine-induced rhabdomyolysis. Ann Pharmacother. 2001 Sep;35(9):1020-3. 

Rosebraugh CJ, Honig PK, Yasuda SU, Pezzullo JC, Flockhart DA, Woosley RL. Formal education about medication errors in internal medicine clerkships. JAMA. 2001 Sep 5;286(9):1019-20. 

Desta Z, Soukhova N, Morocho AM, Flockhart DA. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. J Pharmacol Exp Ther. 2001 Aug;298(2):508-20. 

Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC. In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos. 2001 Jul;29(7):1023-8. 

Jones DR and Hall SD: Calcium Channel Blockers. IN: Metabolic Drug Interactions. Eds.Levy RH, Thummel KE, Trager WF, Harsten PD and Eichelbaum M. Lippincott-Raven Pub, Philadelphia, PA, 2000.

Brater DC, Hall SD: Effects of the kidney on drug disposition and dosing of drugs in patients with renal insufficiency. IN: The Kidney: Physiology and Pathophysiology. Eds. Seldin DW and Giebisch G. Raven Press, New York, Third edition, 2000.